DIRS.INFO The most relevant business & tech news

AT&T has also begun notifying customers whose personal information was compromised. Photos You Should See View All 60 ImagesFull names, email addresses, mailing address, phone numbers, dates of birth and AT&T account numbers may have also been compromised. HAS AT&T SEEN DATA BREACHES LIKE THIS BEFORE? AT&T has seen several data breaches that range in size and impact over the years. Avoiding data breaches entirely can be tricky in our ever-digitized world, but consumers can take some steps to help protect themselves going forward.

Persons: “, Troy Hunt, we’ve, ”, Hunt, You'll, Matt O'Brien Organizations: Associated Press, AP, Federal Trade Commission Locations: Dallas, Australia, Providence , Rhode Island

DAVOS, Switzerland (AP) — Artificial intelligence is easily the biggest buzzword for world leaders and corporate bosses diving into big ideas at the World Economic Forum’s glitzy annual meeting in Davos. In a sign of ChatGPT maker OpenAI’s skyrocketing profile, CEO Sam Altman is making his Davos debut to rock star crowds, with his benefactor, Microsoft CEO Satya Nadella, hot on his heels. Illustrating AI’s geopolitical importance like few other technologies before it, the word was on the lips of world leaders from China to France. Here's a look at the buzz:OPENAI OPENING BIG AT DAVOSPolitical Cartoons View All 253 ImagesThe leadership drama at the AI world's much-ballyhooed chatbot maker followed Altman and Nadella to the swanky Swiss snows. China, one of the world’s centers of AI development, wants to “step up communication and cooperation with all parties” on improving global AI governance, Li said.

Persons: OpenAI’s, Sam Altman, Satya Nadella, Altman, Nadella, “, OpenAI, Klaus Schwab quizzed, Li Qiang, ”, Li, Ursula von der Leyen, Emmanuel Macron, Google's Bard, he's, can’t, Julie Sweet, Arvind Krishna, Yann LeCun, LeCun, ____ Chan, Matt O'Brien Organizations: Davos, DAVOS, Bloomberg, Microsoft, ”, European, EU, Accenture, AP Locations: DAVOS, Switzerland, Davos, China, France, Swiss, percolated, afterparties, Europe, Britain, Valley, London, Providence , Rhode Island

While OpenAI later transitioned to a for-profit model, its controlling shareholder remains the nonprofit OpenAI Inc. and its board of directors. This unique structure made it possible for four OpenAI board members — the company's chief scientist, two outside tech entrepreneurs and an academic — to oust CEO Sam Altman on Friday. When it was founded, OpenAI’s original board co-chairs were Altman and Tesla CEO Elon Musk. Musk recently launched his own AI startup, xAI, to compete with OpenAI, Microsoft and Google, among others. OpenAI's board members have not responded to requests for comment.

Persons: ChatGPT, OpenAI, Sam Altman, Berkshire Hathaway, OpenAI’s, ”, Sarah Kreps, Altman, Greg Brockman, “, Kreps, Ilya Sutskever, we’ve, Adam D’Angelo, Tasha McCauley, Helen Toner, Reid Hoffman, Will Hurd, Shivon Zilis, Brockman, Elon Musk, Musk, D’Angelo, tweeting, ” He’s, Matt O'Brien, Michael Liedtke Organizations: FRANCISCO, Google, Facebook, OpenAI Inc, Cornell University’s Tech Policy Institute, Microsoft Corp, Microsoft, Georgetown Center for Security, Emerging Technology, Republican U.S . Rep, Tesla, OpenAI, Associated Press Technology Locations: Berkshire, OpenAI, Will Hurd of Texas, Providence , Rhode Island, San Francisco

At OpenAI, Shear has promised to shed some light into Altman’s departure. In his X post, he pledged to hire an independent investigator to look into what led up to Altman’s ouster and write a report within 30 days. Both Altman and Shear know each other as alumni from the first class of startup founders at Y Combinator. In his post on X, Shear wrote he received a call offering him a “once-in-a-lifetime opportunity” to become interim CEO at San Francisco-based OpenAI. In his post on X, Shear said he checked the reasoning behind the changes at OpenAI before he took the job.

Persons: Twitch, Sam Altman, Emmett Shear, “, Altman, OpenAI, Greg Brockman —, —, Shear, Twitch doesn’t, it’s, Y, he’s, ”, Mira Murati, Altman’s, Satya Nadella, Brockman, Sam, “ I’m, “ It’s, ” Shear, Matt O'Brien Organizations: Twitter, Microsoft, Amazon, Yale University, Associated Press, Investors, AIs Locations: Buffalo , New York, Germany, San Francisco, Providence , Rhode Island

☆ These losing stocks could surge as the year winds down, Bank of America says
▼ + stars: | 2023-11-10 | by ( Darla Mercado | Cfp | ) www.cnbc.com time to read: +3 min

One investor's portfolio loser could be another's winning stock as 2023 draws to a close, according to Bank of America. Buy rated and cheap Bank of America screened for buy-rated stocks that fell at least 10% in 2023 through the end of October that were also overweight by long-only funds as of September. However, Bank of America still rates both names as buys – and others on Wall Street spot potential. Retailer Target is another name that made the cut, garnering a buy rating from Bank of America. Other stocks in Bank of America's list include agriculture play Mosaic , life insurer MetLife , defense giant Northrop Grumman , as well as gas and electric utility CenterPoint Energy .

Persons: Savita Subramanian, Dexcom, Insulet, –, Piper Sandler's Matt O'Brien, — CNBC's Michael Bloom Organizations: Bank of America, Internal Revenue, Bank of, Target, MetLife, Northrop, CenterPoint Energy Locations: Bank of America, Bank

☆ Many are betting Ozempic will reduce the need for knee surgery. What it means if they're wrong
▼ + stars: | 2023-10-14 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Medical device stocks of all kinds were pummeled over the past week as investors tried to calculate the ripple effects of new weight loss drugs. While the use of the GLP-1 drugs to treat obesity is still very limited at this point, it is expected to soar to a $100 billion market or more, by some estimates. Judging by the momentum in the stocks, investors have been betting that as people lose weight, there will be a decline in knee replacement surgery. A case for more knee surgery? Based on Truist's polling of 50 hospital administrators, the analyst expects the third quarter will show a slowing pace of knee replacement surgeries compared to the first half of 2023.

Persons: We've, Bill Sutherland, Piper Sandler, Matt O'Brien, Stryker, Eli Lilly's Mounjaro, O'Brien, Richard Newitter, Newitter, Benchmark's Sutherland, Kaiser, Sutherland, — CNBC's Michael Bloom Organizations: American College of, Nordisk's Ozempic, Stryker, Surgery Partners, Permanente, Tenet Healthcare, Partners Locations: U.S, GLP

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
▼ + stars: | 2023-09-08 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won't hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren't buying it. The answer may depend on who you listen to and whether you see GLP-1 drugs as a help or a hinderance to the category. DXCM 3M mountain In the quarter to date, Dexcom shares are down nearly 19%. Dexcom shares are down more than 7% year to date. TNDM 3M mountain Tandem Diabetes shares have fallen significantly this year.

Persons: Ozempic, Danielle Antalffy, Eli Lilly's Mounjaro, hasn't, Dexcom, Piper Sandler, Matt O'Brien, O'Brien, Paresh Dandona, semaglutide, Travis Steed, Steed, — CNBC's Michael Bloom Organizations: UBS, Nordisk's, Novo, New, of Medicine, Tandem Diabetes, Tandem Diabetes Care, Diabetes, Jacobs School of Medicine, Biomedical Sciences, University of Buffalo, Novo Nordisk's, Bank of America Locations: CGMs

☆ These medical device makers are driving a 'paradigm' shift in cardiac care, Piper Sandler says
▼ + stars: | 2023-06-19 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

A safer, quicker way to treat some heart arrhythmia cases could be on the horizon, creating an opportunity for medical device companies Boston Scientific and Medtronic, according to Piper Sandler analyst Matt O'Brien. He estimates that Boston Scientific will ring up $454 million in sales by 2025 for its Farapulse catheter. Meanwhile, Boston Scientific shares hit a record high on Friday. BSX YTD mountain Boston Scientific shares have gained more than 17% so far this year. He expects that this could prompt consolidation, providing a way for any larger AF treatment providers that have fallen behind on innovation to catch up.

Persons: Piper Sandler, Matt O'Brien, O'Brien, Medtronic, Medtronic's, Abbott, Johnson Organizations: Boston Scientific, Centers for Disease Control, PFA, Boston, EU Locations: U.S

☆ This medtech stock has a 'pathway to $1B in sales' by 2030, Piper Sandler says
▼ + stars: | 2023-06-07 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

It's time to buy Glaukos ahead of some "exciting" product launches, Piper Sandler said. Analyst Matt O'Brien upgraded Glaukos to overweight, saying investors are overlooking the potential in its treatments for glaucoma, corneal disorders and retinal diseases — namely, iDose and iStent. GKOS 1D mountain Glaukos shares 1-day Glaukos shares are outstripping the major benchmarks this year, climbing 52% in 2023, while the S & P 500 is up 11%. Regardless, the analyst's $80 price target suggests shares have further to climb — more than 23% from Tuesday's closing price of $64.82. In particular, he called iDose the "most exciting" launch in midcap medtech, as he expects the treatment will be quickly adopted.

Persons: Piper Sandler, Matt O'Brien, O'Brien, Michael Bloom Locations: midcap

☆ Microsoft limits Bing chat exchanges and conversation lengths after 'creepy' interactions with some users
▼ + stars: | 2023-02-18 | by ( Jyoti Mann | ) www.businessinsider.com time to read: +3 min

Microsoft is limiting Bing's conversation lengths and interactions with users, per a blog post. It has imposed a limit of 50 chat turns a day and 5 chat turns each session. Microsoft said the underlying chat model can get "confused" by "very long" conversations. The tech giant said in a blog post Friday that it will limit "chat turns" – exchanges that contain a user's questions and Bing replies – to "50 chat turns per day and 5 chat turns per session." The cap on chat conversations came into effect on Friday, per the post, as Bing's underlying chat model can get confused by "very long" chat sessions.

Search resuls for: "Matt O'Brien"

11 mentions found